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The management of recurrent glioblastoma is highly challenging, and treatment outcomes remain uniformly poor. Glioblastoma
is a highly inﬁltrative tumor, and complete surgical resection of all microscopic extensions cannot be achieved at the time of
initial diagnosis, and hence local recurrence is observed in most patients. Gamma Knife radiosurgery has been used to treat these
tumor recurrences for select cases and has been successful in prolonging the median survival by 8–12 months on average for
select cases. We present the unique case of a 63-year-old male with multiple sequential recurrences of glioblastoma after initial
standard treatment with surgery followed by concomitant external beam radiation therapy and chemotherapy (temozolomide).
The patient was followed clinically as well as with surveillance MRI scans at every 2-3-month intervals. The patient underwent
Gamma Knife radiosurgery three times for 3 separate tumor recurrences, and the patient survived for seven years following the
initialdiagnosiswiththisaggressivetreatment.Themediansurvivalinpatientswithrecurrentglioblastomaisusually8–12months
after recurrence, and this unique case illustrates that aggressive local therapy can lead to long-term survivors in select situations.
We advocate that each patient treatment at the time of recurrence should be tailored to each clinical situation and desire for quality
of life and improved longevity.
1.Introduction
Glioblastoma multiforme (GBM) accounts for more than
50% of all gliomas and is the most aggressive type of primary
brain tumor arising from glial cells. These tumors account
for approximately 50% of all parenchymal brain tumor cases
and 20% of all intracranial tumors. Approximately 10,000–
25,000 cases are diagnosed annually in the United States
[1, 2]. The peak incidence is around 45–55 years of age [3].
Despite advances in cancer therapy, treatment of gliobla-
stoma remains a challenging issue and requires tailoring
of treatment to each patient’s clinical situation. Rarely
are the available treatments curative, even with aggressive
multimodality treatment regimens (surgery, radiation and
chemotherapy) [4]. Studies have shown that the extent or
completeness of resection has been correlated with survival
[5,6].Uponinitialdiagnosis,thestandardtreatmentconsists
of maximal surgical resection, fractionated external beam
radiation (standard dose ranges between 5940 and 6000cGy
in 180–200cGy per fraction), and concomitant and adjuvant
chemotherapy with temozolamide. The progression-free
survival with multimodality treatment is between 8 and
12 months. Despite multimodality treatment, the reported
median survival is about 14–18 months [7].2 Case Reports in Medicine
Treatment options for recurrent GBM include chemo-
therapy, reirradiation, surgery, radiosurgery, antiangiogenic
therapy, gene therapy, or best supportive care with corticos-
teroids [8, 9]. Treatment should be tailored to the individual
situation, and the goal is to avoid the sequelae of iatrogenic
neurotoxicity while maintaining a reasonable quality of life.
Surgical resection is not an option for most patients in the
recurrent setting, given the inﬁltrative nature of gliomas and
proximity of the tumor to critical neurological structures.
Reirradiation with conventional external-beam radiotherapy
produces only a modest beneﬁt in most patients, and in
many situations, the risks outweigh the potential beneﬁts
[10]. Options are limited by the previous high doses of
radiotherapy applied after the primary diagnosis, the tumor
volume, and location at the time of recurrence. The response
to systemic chemotherapy is also modest although new
agents are being used such as bevacizumab (FDA approved
for disease recurrence) [11]. Other options for treatment in
the recurrent setting include combination or single agent
chemotherapy, brachytherapy, and/or stereotactic radiation
[12–16].
Stereotactic radiotherapy can be applied in a single
fraction as stereotactic radiosurgery (SRS), or as fractionated
stereotactic radiotherapy (FSRT) in which multiple fractions
are given over a period of 2–4 weeks [16–20]. In this paper,
wediscusstheuniquetreatmentresultsforapatientwhowas
successfullytreatedwithGKradiosurgeryonthreesequential
occasions after recurrence and who survived for 7 years
following the initial diagnosis.
2.CaseReport
We present the unique case of a 63-year-old gentleman who
initially presented with a ﬁve-week history of headaches
behindtherighteye,withassociated“dizziness.”Twomonths
prior to this, he had a syncopal episode. A CT scan at
that time without contrast was reported as normal. On
presentation, his wife noted that the patient needed help
while getting dressed and was dragging his left leg, and
he experienced weakness of the left hand. There were no
complaints of nausea, vomiting, numbness, weakness, or any
visual changes. His past medical history was signiﬁcant for
hypothyroidism and hyperlipidemia.
Physical examination of the patient revealed that he had
aﬂ a ta ﬀect, his verbal responses were slow, and he was alert,
oriented, and exhibited a ﬂattened nasolabial fold on the
left. Motor examination revealed equal strength and normal
reﬂexes bilaterally in the upper arms, but slightly hypoactive
patellar reﬂexes and ankles with downgoing plantars on the
left. Cranial nerve examination was normal. A CT scan with
and without contrast revealed a large, irregularly enhancing
mass in the right temporal lobe that was associated with
marked edema and mass eﬀect, with mild uncal herniation
and left shift suggestive of a brain tumor, suspicious of GBM.
Following the consultation with a neurosurgeon and
discussing the possibility of a brain tumor and treatment
options, the patient underwent a right temporal lobe
lobectomy. The ﬁnal pathology was consistent with GBM.
Figure 1: Gamma Knife treatment planning illustration of dose on
an axial T1 postgadolinium MRI scan for the ﬁrst Gamma Knife
treatment.
The patient recovered well from surgery, and his headaches
and dizziness were resolved with dexamethasone. Adjuvant
treatment options were explained to him and included post-
operative radiation with concurrent chemotherapy (temo-
zolomide). The patient underwent radiation to a total dose
of 6100cGy with no complications. He took temozolomide
only for a couple of months in the adjuvant setting, and this
was discontinued due to side eﬀects.
One month after treatment, a followup scan revealed
some residual enhancement in the operative bed consistent
with residual/recurrent tumor versus radiation change. An
MRI performed 12 weeks after treatment showed an increase
in enhancement of the resection bed, and this was consistent
with residual tumor. As the patient already had a full course
of external beam radiation, the option of being treated with
GK radiosurgery was presented, and the risks and beneﬁts
were discussed with the patient. The patient consented,
and GK radiosurgery was successfully completed without
complications. The marginal prescription dose was 16Gy
to the 45% isodose line for a 3.5cm diameter region (see
Figure 1).
Following his GK therapy, he was followed clinically as
well as with surveillance MRI scans at 2-3-month intervals.
Also, he was placed on monthly adjuvant Temozolomide,
which was prescribed for 5 days of every 28-day cycles
according to standard protocols. An MRI scan 4 months
after his GK treatment again revealed an irregularly enhanc-
ing mass in the right temporal lobe which had enlarged
signiﬁcantly compared to the previous MRI two months
prior. This was felt to represent recurrence and not radiation
necrosis and was conﬁrmed by review of this in light
of past imaging studies with neuroradiology. The patient
also described brief neurological symptoms at this time,
with diﬃculty buttoning his shirt. However, this quickly
resolved with dexamethasone therapy. Treatment options
were again discussed and included repeat surgery (which
would have been technically diﬃcult and would have beenCase Reports in Medicine 3
Figure 2: Gamma Knife treatment planning illustration of dose on
an axial T1 postgadolinium MRI scan for the third Gamma Knife
treatment.
associated with signiﬁcant risks) versus undergoing repeat
GK radiosurgery. The patient consented to repeat GK and
successfully underwent the procedure a second time without
complications. The second GK dose prescribed to the 50%
isodose line was 14Gy to a 4.2cm diameter region.
Again, the patient was followed with serial MRI scans
at two- to three-month intervals as well as clinically and
again was found to have radiographic documentation of
disease recurrence 14 months following his last treatment.
He again consented to a third treatment with GK. For his
third GK treatment, the dose prescribed to the 50% isodose
line was 12Gy to a 4.9cm diameter region (see Figure 2).
Following his third and ﬁnal GK treatment, the patient
survived a total of 69 months. During the ﬁnal years of
his life, the patient developed dizziness, confusion, visual
problems, seizures, and weakness. He also developed new
onset diabetes for which he was put on insulin. The patient
gradually became wheel chair bound and later developed
lower extremity DVT. He was not anticoagulated because of
increased risk of cerebral bleeding due to the inﬁltrating and
enlarging nature of the tumor. Recommendation was made
for hospice, but the patient refused and later succumbed to
his disease at home.
3. Discussion
Although the prognosis of patients with glioblastoma is uni-
formly poor, treating the patients in an attempt to improve
the quality of life and longevity is of utmost importance.
Variables predicting longer survival in several studies include
extent of resection (gross total versus subtotal), younger age
(<50 years), higher Karnofsky performance scores (KPS),
normal mental status, and smaller tumor volume [21, 22].
MGMT methylation is also associated with longer survival,
and a testing option for this is commercially available [23].
Ampliﬁcation and activating mutations of the epidermal
growth factor receptor (EGFR) oncogene are also common
in glioblastomas [24, 25]. However, much remains unknown
about why some patients survive longer with glioblastoma
[26–29].
Many chemotherapeutic agents, either as single agents or
in combination chemotherapy regimens, have been used to
treat recurrent malignant gliomas [30, 31]. Temozolomide,
PCV, bevacizumab are some of the treatment options [32–
35]. Bevacizumab has been approved by FDA for the
treatment of recurrent GBMs [11]. Temsirolimus (CCI-
779), a small-molecule inhibitor of the mammalian target of
rapamycin (mTOR), has shown activity in recurrent gliomas
[36]. Erlotinib and other EGFR inhibitors have been studied
in combination with radiation therapy [37, 38].
Given that recurrence has been postulated to be sec-
ondary to persistent stem cells, vaccine therapy has been
attempted in relapsed cases [39]. Small trials have reported
that a tumor B-cell hybridoma vaccine against tumor
stem cells elicited a speciﬁc tumor immune reaction thus
enhancing immune response to the disease [40]. Larger trials
are in progress to further assess this approach to treating
glioblastoma.
Brachytherapy for recurrent disease using high-activity
I-125 interstitial implants has been shown to improve
median survival in highly selected patients to around 8
months [13, 35]. Glia-Site brachytherapy, using an inﬂatable
balloon catheter implanted into the surgical resection cavity
for delivery of homogeneous low-dose rate radiation, has
also shown promising results in patients with recurrent
gliomas [41]. Radiation in the form of brachytherapy is
highly invasive; thus, this technique is often associated with
high morbidity and therefore limited to small subgroup of
patients.
SRS has the ability to precisely deliver high doses of
radiation to a deﬁned tumor volume in a single fraction
with less treatment-associated morbidity compared with
surgery. FSRT involves delivering radiation to a deﬁned
tumor volume, exploiting the radiobiologic advantage of
fractionation, and thus minimizing the risk of serious side
eﬀects [42]. Stereotactic external beam radiotherapy can be
applied in single fractions as SRS or as FSRT in which
multiple fractions are given over a period of 2–4 weeks. With
thisapproach,thedosewithinthetumorismuchhigherthan
thedoseinthesurroundingnormalbraintissue,asaresultof
sharp dose gradient achieved by multiple converging beams
of radiation. The three most common types of radiation
therapy devices used are Cobalt-60-based machines, linear
accelerators, and cyclotrons which use gamma rays, X-rays,
and protons, respectively.
TheRTOGconductedamulticenteredrandomizedphase
III trial analyzing the addition of SRS to standard exter-
nal beam radiation therapy (EBRT) for the treatment of
glioblastoma. In this trial, SRS was used as part of the initial
management rather than as a salvage therapy. 203 patients
with supratentorial glioblastoma were randomly assigned
to receive either postoperative SRS followed by EBRT
and carmustine, or EBRT and carmustine without SRS.
They observed no statistically signiﬁcant diﬀerences between
the two groups of patients with regard to the primary
endpoint of survival around 13.5 months [43]. However,
a number of institutional reviews have been reported that4 Case Reports in Medicine
show encouraging results including survival prolongation in
the recurrence setting for speciﬁc patients. The timing of
SRS and lack of careful patient selection may explain the
apparent lack of beneﬁt in this setting. Patients are selected
based on age, performance status, extracranial volume of
disease, intracranial tumor volume, and by histologic type
and number of brain metastases. We utilize a standard
treatment algorithm at our institution based on tumor size,
proximity of nearby critical structures, and prior radiation
treatment received. This algorithm is adapted to published
clinical research on radiation doses, volumes, and accepted
treatment techniques.
Combs et al. reported long-term results in 172 patients
treatedinasingleinstitutionhighlightingtheeﬃcacyoffrac-
tionated stereotactic reirradiation in recurrent gliomas [19].
Between 1990 and 2004, 172 patients with recurrent gliomas
were treated with FSRT as reirradiation. Approximately 59
patients were diagnosed with GBM, and the median time
between primary radiotherapy and reirradiation was 10
months for GBM. FSRT was performed with a median dose
of 36Gy in a median fractionation of 10Gy/wk. Median
overall survival after primary diagnosis was 21 months
for patients with glioblastoma. Time to progression and
histology were signiﬁcant factors inﬂuencing survival after
reirradiation. Progression-free survival after FSRT was 5
months. Villavicencio et al. reported their experience with
twenty patients who underwent Cyber Knife treatment at
the time of the initial diagnosis and/or during the ﬁrst 3
months of their initial clinical management [44]. Twenty
six patients were treated at the time of tumor recurrence or
progression. Cyber Knife was performed in addition to the
traditional therapy. The median survival from diagnosis for
the patients treated with Cyber Knife as an initial clinical
therapy was 11.5 months (range, 2–33) compared to 21
months (range, 8–96) for the patients treated at the time of
tumor recurrence/progression. This diﬀerence was reported
to be statistically signiﬁcant (Kaplan-Meier analysis, P =
0.0004). The median survival from the Cyber Knife treat-
mentwas9.5months(range,0.25–31months)and7months
(range, 1–34 months) for patients in the newly diagnosed
and recurrent GBM groups (Kaplan-Meier analysis, P =
0.79), respectively. Patients with more extensive surgical
interventions survived longer (P = 0.008), especially those
who underwent total tumor resection versus biopsy (P =
0.004). This revealed that there was no apparent survival
advantage in using CyberKnife in the initial management of
glioblastoma patients, and it should be reserved for patients
whose tumors recur or progress after conventional therapy.
The above trials show the eﬀectiveness of SRS as an
option for the treatment of recurrent glioblastoma. Eﬀective
implementation of stereotactic radiosurgery requires a team
of well-trained neurosurgeons, radiation oncologists, med-
ical oncologists, and medical physicists who work together
as a part of multidisciplinary team. GK requires localization
and immobilization of the target with the attachment of
head frame to the skull. With local anesthesia, four screws
pierce the scalp and secure the frame to the outer table of
the skull. MRI is then performed to localize the target(s) in
three dimensions. With the help of high-speed computers,
physicians and the physicists develop a treatment plan that
focuses the radiation as precisely as possible on the tumor
target. After the treatment is complete, the head frame is
removed, and the patient is usually discharged within an
hour. Some patients may require pain medications after the
frame removal, which occasionally delays discharge. Many
patients are able to resume routine activities within a week
after the procedure. The followup of patients at our center
consists of an MRI after a month and thereafter every 2-3
months to assess for local control and tumor recurrence.
4. Conclusion
This is the ﬁrst reported case to our knowledge of a
patient with recurrent glioblastoma who survived seven
years following treatment with GK radiosurgery. The patient
underwent salvage treatment two additional times during
the 7 year period and tolerated the therapy well. This
case highlights the unique biology of individual tumors
and that focused radiation in the recurrent setting can
signiﬁcantly impact overall survival for speciﬁc patients.
We look forward to continued research in this area as well
as into the molecular characteristics of individual tumors.
Continued individualization of treatment for each unique
patient’s situation will allow for improvements in survival as
well as quality of life.
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